Why a single number in millimeters shapes your stage, treatment, and outlook
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
If you or a loved one has been diagnosed with melanoma, one number on the pathology report tends to come up again and again in conversations with your care team: Breslow depth. It's usually written as a decimal followed by "mm"—something like "0.6 mm" or "2.3 mm."
That small number carries outsized weight. Breslow depth is widely considered the single most important prognostic factor in early-stage melanoma, and it directly shapes your stage, your surgery, and whether additional procedures like a sentinel lymph node biopsy are recommended. This guide explains what Breslow depth is, how it's measured, and why it matters so much.
Breslow depth (also called Breslow thickness) is a measurement of how far a melanoma has grown downward into the skin, expressed in millimeters. It's named for Dr. Alexander Breslow, the pathologist who first showed in 1970 that tumor thickness predicted survival better than the staging methods used at the time.
Technically, it's measured from the top of the granular layer of the epidermis (the outermost living layer of skin)—or from the base of an ulcer, if the tumor surface has broken down—straight down to the single deepest melanoma cell the pathologist can find under the microscope. It is not the same as how wide the mole looked on your skin, and it isn't something you or your doctor can estimate by eye; it can only be measured accurately on tissue under a microscope after a biopsy.
After a biopsy or excision, the tissue is processed, sliced into very thin sections, mounted on slides, and stained (typically with hematoxylin and eosin) so the pathologist can see individual cells under the microscope.
Using an eyepiece fitted with a calibrated ocular micrometer, the pathologist measures the vertical distance from the starting point (top of the granular layer, or ulcer base) to the deepest identifiable melanoma cell, recorded to the nearest tenth of a millimeter.
Because this is a manual measurement on a physical slide, results can shift a little depending on how the tissue was cut or oriented—which is one reason a second pathology opinion is sometimes requested for melanomas that fall right at a staging cutoff, such as 0.8 mm or 1.0 mm. See our guide to understanding your melanoma pathology report for more on what else appears alongside Breslow depth.
Decades of outcomes data, going back to Dr. Breslow's original 1970 study, have consistently shown that survival tracks closely with tumor thickness. As a general pattern:
These are general patterns, not guarantees—other pathology findings like ulceration, and your own health history, also factor into your individual outlook. Ulceration in particular can shift risk upward even at the same thickness.
Under the American Joint Committee on Cancer (AJCC) staging system, Breslow depth is the primary factor used to assign the "T" (tumor) category—T1 through T4—with ulceration as a secondary modifier at each level:
The T category, combined with lymph node (N) and metastasis (M) findings, is what ultimately determines your overall stage (0–IV). For the full picture of how staging works and what each stage means for treatment and outlook, see our guide on what your melanoma stage means.
After a melanoma diagnosis, surgery to remove additional healthy-looking skin around the original site (a "wide local excision") is standard, and the recommended margin width is set largely by Breslow depth. Thin melanomas (≤1 mm) are generally treated with a 1 cm margin, melanomas 1–2 mm thick with a 1–2 cm margin, and melanomas thicker than 2 mm with a 2 cm margin. These thresholds come from randomized trials comparing narrower and wider margins at different thicknesses.
Breslow depth is also the main factor used to decide whether a sentinel lymph node biopsy (SLNB) should be offered. Current guidelines generally do not recommend SLNB for melanomas thinner than about 0.8 mm without other high-risk features, since the chance of a positive node is very low. SLNB is typically recommended for melanomas ≥1 mm, and may be discussed on a case-by-case basis for melanomas between 0.8 and 1.0 mm with additional risk factors such as ulceration. Learn more in our guide to sentinel lymph node biopsy.
Thicker melanomas, or those found to have spread to a lymph node, more often lead to discussions about adjuvant immunotherapy or targeted therapy, and closer follow-up schedules. See our guide on melanoma treatment options by stage for how these decisions unfold.
Breslow depth can feel like just one more number on a dense report, but it's the thread that connects nearly every major decision in early melanoma care—from how your tumor is staged, to how wide a margin your surgeon removes, to whether a sentinel lymph node biopsy makes sense for you.
Ask your dermatologist or surgical oncologist to walk you through your own Breslow depth and what it means for your specific plan. Understanding this one measurement can make the rest of your pathology report—and your treatment path—much easier to follow.
Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for personalized information about your Breslow depth and staging
Chat with the Navigator